Market Overview

Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

Related AMRN
Week Concludes With S&P 500 Below 2,000; Dow Below 17,000
Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings Report

In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating and $20.00 price target on Amarin Corporation plc (NASDAQ: AMRN).

In the report, Jefferies noted, “We outline several reasons why we remain positive on near term approval prospects for the Vascepa ANCHOR indication in advance of the advisory committee meeting set for October 16 and the expected release of the FDA's briefing documents on Friday (October 11). The ANCHOR Indication of mixed dyslipidemia is critical for long-term Vascepa sales growth and we view it as central to our AMRN Buy thesis.”

Amarin Corporation plc closed on Wednesday at $6.30.

Latest Ratings for AMRN

DateFirmActionFromTo
May 2014CitigroupDowngradesBuyNeutral
Feb 2014Aegis CapitalMaintainsHold
Jan 2014MKM PartnersDowngradesBuyNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WeiAnalyst Color Reiteration Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters